Hematology

A groundbreaking multinational clinical trial, named RESILIENCE, is underway to test a promising new treatment aimed at preventing heart damage caused by…

Children with ALL who are overweight or obese at multiple points during treatment have worse survival rates and higher relapse risk, according to a cohort study of 794 patients.

A new cohort study analysing over 100,000 A&E visits in North Carolina has redefined what constitutes high emergency care use among people with sickle cell disease.

A large-scale US study reveals that 34% of sickle cell disease patients are readmitted within 30 days of hospital discharge, nearly triple the rate of non-SCD patients.

In a major study presented at EHA, Noella Collado-Gisbert demonstrated that residual disease kinetics are a strong predictor of survival in multiple myeloma.

Recognised with an EHA Young Abstract award, Hangjie Fu’s study reveals that ellagic acid significantly mitigates liver injury caused by iron overload.

The Phase II CONCEPT trial has demonstrated that an isatuximab-based combination therapy achieves unprecedented rates of minimal residual disease negativity in patients with high-risk newly diagnosed multiple myeloma.

A large European analysis confirms circulating tumour cells (CTCs) as an independent prognostic biomarker in newly diagnosed multiple myeloma.